In recent years, imaging tumors with receptor-specific biomolecules has been the focus of increasing interest. Vasoactive intestinal peptide (VIP)(VPAC) has a high affinity for specific receptors that are expressed in high density on many malignant tumors.
Publications
99mTcLabeled Vasoactive Intestinal Peptide Analog for Rapid Localization of Tumors in Humans
Recent Posts
- NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer
- Targeting VPAC1 Receptors for Imaging Glioblastoma
- NuView Life Sciences Creates Subsidiary for Latin American Market
- Jay Bishoff, MD, joins The Smith Institute for Urology
- Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics
Archives
- October 2022
- January 2022
- November 2021
- August 2021
- February 2021
- January 2021
- November 2020
- August 2020
- June 2020
- May 2020
- October 2019
- September 2019
- August 2019
- July 2019
- April 2019
- March 2019
- January 2019
- November 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- March 2013
- February 2013
- February 2000
- January 2000
Recommended For You
Publications
Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics
Karla Jo HelmsFebruary 28, 2021